To include your compound in the COVID-19 Resource Center, submit it here.

Hua shows sustained benefit in diabetics with glucokinase activator

Hua announced Phase III follow-up data showing its first-in-class diabetes therapy led to sustained HbA1c reductions at one year -- a long-term effect that EVP and CFO George Lin told BioCentury hasn’t been observed with most

Read the full 368 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers